^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FT-6876

    i
    Other names: FT-6876
    Company:
    Novo Nordisk
    Drug class:
    CBP inhibitor, EP300 inhibitor
    Related drugs:
    1year
    FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer. (PubMed, Target Oncol)
    Our findings demonstrate FT-6876 as a promising new CBP/p300 bromodomain inhibitor, with efficacy in preclinical models of AR+ breast cancer.
    Preclinical • Journal
    |
    ER (Estrogen receptor) • AR (Androgen receptor)
    |
    AR positive • AR expression • ER expression
    |
    FT-6876
    almost4years
    [VIRTUAL] FT-6876, a potent and selective inhibitor of CBP/p300 with antitumor activity in AR-positive breast cancer (AACR-II 2020)
    This was associated with a reduction in H3K27Ac, AR and ER target gene modulation, and reduction in Ki67. FT-6876 is a promising new CBP/p300 bromodomain inhibitor demonstrating efficacy in preclinical models of AR+ breast cancer.
    PARP Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • AR (Androgen receptor)
    |
    AR positive • AR expression
    |
    FT-6876